Key Points
- CEO Seth Lederman bought 5,000 shares at an average price of $4.05, a $20,250 purchase that increased his ownership by 45.43% to 16,005 shares.
- Tonix shares were down 16.3% and opened at $3.24, near their 12-month low of $3.21.
- The company reported a quarterly loss of $2.89 per share, missing estimates of $2.39, while revenue of $17.23 million topped expectations of $16.32 million. Analysts’ consensus rating was Buy, with a $22.33 target price.
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) CEO Seth Lederman acquired 5,000 shares of the company's stock in a transaction that occurred on Wednesday, November 11th. The shares were acquired at an average price of $4.05 per share, with a total value of $20,250.00. Following the acquisition, the chief executive officer owned 16,005 shares in the company, valued at $64,820.25. This trade represents a 45.43% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Seth Lederman also recently made the following trade(s):
- On Thursday, August 27th, Seth Lederman acquired 2,000 shares of Tonix Pharmaceuticals stock. The stock was acquired at an average cost of $13.79 per share, for a total transaction of $27,580.00.
Tonix Pharmaceuticals Stock Down 16.3%
TNXP stock opened at $3.24 on Friday. The business's fifty day simple moving average is $7.93 and its two-hundred day simple moving average is $11.92. Tonix Pharmaceuticals Holding Corp. has a twelve month low of $3.21 and a twelve month high of $20.56. The firm has a market cap of $62.95 million, a price-to-earnings ratio of -0.26 and a beta of 1.90.
Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($2.89) earnings per share for the quarter, missing the consensus estimate of ($2.39) by ($0.50). The business had revenue of $17.23 million for the quarter, compared to the consensus estimate of $16.32 million. Tonix Pharmaceuticals had a negative return on equity of 80.97% and a negative net margin of 420.45%. Research analysts expect that Tonix Pharmaceuticals Holding Corp. will post -10.42 EPS for the current year.
Hedge Funds Weigh In On Tonix Pharmaceuticals
Institutional investors have recently bought and sold shares of the business. Global Retirement Partners LLC bought a new position in Tonix Pharmaceuticals in the third quarter worth approximately $28,000. Integrated Wealth Concepts LLC purchased a new stake in Tonix Pharmaceuticals during the second quarter worth $92,000. Great Lakes Advisors LLC bought a new stake in Tonix Pharmaceuticals during the 2nd quarter valued at $303,000. Bank of New York Mellon Corp bought a new stake in Tonix Pharmaceuticals during the 2nd quarter valued at $533,000. Finally, Bank of America Corp DE boosted its position in Tonix Pharmaceuticals by 101.1% during the 1st quarter. Bank of America Corp DE now owns 60,958 shares of the company's stock valued at $838,000 after acquiring an additional 30,644 shares in the last quarter. 82.26% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several research analysts recently commented on the stock. Canaccord Genuity Group assumed coverage on shares of Tonix Pharmaceuticals in a research note on Monday, October 26th. They issued a "buy" rating and a $18.00 price target on the stock. Weiss Ratings reissued a "sell (e+)" rating on shares of Tonix Pharmaceuticals in a research report on Monday, October 26th. Raymond James Financial reissued a "strong-buy" rating on shares of Tonix Pharmaceuticals in a research report on Tuesday, October 20th. Finally, Wall Street Zen upgraded shares of Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Sunday, October 4th. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $22.33.
Check Out Our Latest Stock Report on Tonix Pharmaceuticals
Tonix Pharmaceuticals Company Profile
(
Get Free Report)
Tonix Pharmaceuticals Holding Corp. is a U.S.-based biopharmaceutical company that develops and commercializes medicines for central nervous system disorders and pursues research programs in immunology, rare diseases and infectious diseases. Its product Tonmya (cyclobenzaprine hydrochloride sublingual tablets) received U.S. Food and Drug Administration approval in 2025 for the treatment of fibromyalgia in adults. The company also has a development pipeline that includes drug candidates and vaccine programs, including research targeting smallpox and mpox.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
